TIA-1 Cytotoxic Granule-Associated RNA Binding Protein Improves the Prognostic Performance of CD8 in Mismatch Repair-Proficient Colorectal Cancer

Background Evidence suggests a confounding effect of mismatch repair (MMR) status on immune response in colorectal cancer. The identification of innate and adaptive immune cells, that can complement the established prognostic effect of CD8 in MMR-proficient colorectal cancers patients, representing 85% of all cases, has not been performed. Methodology/Principal Findings Colorectal cancers from a test (n = 1197) and external validation (n = 209) cohort of MMR-proficient colorectal cancers were mounted onto single and multiple punch tissue microarrays. Immunohistochemical quantification (score 0-3) was performed for CD3, CD4, CD8, CD45RO, CD68, CD163, FoxP3, GranzymeB, iNOS, mast cell tryptase, MUM1, PD1 and TIA-1 tumor-infiltrating (TILs) reactive cells. Coexpression experiments on fresh colorectal cancer specimens using specific cell population markers were performed. In the test group, higher numbers of CD3+ (p<0.001), CD4+ (p = 0.029), CD8+ (p<0.001), CD45RO+ (p = 0.048), FoxP3+ (p<0.001), GranzymeB+ (p<0.001), iNOS+ (p = 0.035), MUM1+ (p = 0.014), PD1+ (p = 0.034) and TIA-1+ TILs (p<0.001) were linked to favourable outcome. Adjusting for age, gender, TNM stage and post-operative therapy, higher CD8+ (p<0.001; HR (95%CI): 0.66 (0.64-0.68)) and TIA-1+ (p<0.001; HR (95%CI): 0.56 (0.5-0.6)) were independent prognostic factors. Moreover, among patients with CD8+ infiltrates, TIA-1 further stratified 355 (35.6%) patients into prognostic subgroups (p<0.001; HR (95%CI): 0.89 (95%CI: 0.8-0.9)). Results were confirmed on the validation cohort (p = 0.006). TIA-1+ cells were mostly CD8+ (57%), but also stained for TCRγδ (22%), CD66b (13%) and only rarely for CD4+, macrophage and NK cell markers. Conclusions TIA-1 adds prognostic information to TNM stage and adjuvant therapy in MMR-proficient colorectal cancer patients. The prognostic effect of CD8+ TILs is confounded by the presence of TIA-1+ which translates into improved risk stratification for approximately 35% of all patients with MMR-proficient colorectal cancers.

[1]  L. Terracciano,et al.  High frequency of tumor‐infiltrating FOXP3+ regulatory T cells predicts improved survival in mismatch repair‐proficient colorectal cancer patients , 2010, International journal of cancer.

[2]  Masao Tanaka,et al.  Intratumoral CD8+ T/FOXP3+ cell ratio is a predictive marker for survival in patients with colorectal cancer , 2010, Cancer Immunology, Immunotherapy.

[3]  T. Marafioti,et al.  Immune phenotype predicts risk for posttransplantation squamous cell carcinoma. , 2010, Journal of the American Society of Nephrology : JASN.

[4]  H. Putter,et al.  The Predictive Value of HLA Class I Tumor Cell Expression and Presence of Intratumoral Tregs for Chemotherapy in Patients with Early Breast Cancer , 2010, Clinical Cancer Research.

[5]  W. Sauerbrei,et al.  Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines , 2009, British Journal of Cancer.

[6]  T. Molina,et al.  Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. , 2009, Blood.

[7]  Pornpimol Charoentong,et al.  Coordination of intratumoral immune reaction and human colorectal cancer recurrence. , 2009, Cancer research.

[8]  N. Zeps,et al.  Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  N. Chaput,et al.  Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue , 2008, Gut.

[10]  S. Kitano,et al.  Prognostic value of tumor-infiltrating FOXP3+ regulatory T cells in patients with hepatocellular carcinoma. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  John D Potter,et al.  Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. , 2007, Gastroenterology.

[12]  D. O’Malley.  T-cell large granular leukemia and related proliferations. , 2007, American journal of clinical pathology.

[13]  J. Jass,et al.  Differential significance of tumour infiltrating lymphocytes in sporadic mismatch repair deficient versus proficient colorectal cancers: a potential role for dysregulation of the transforming growth factor-beta pathway. , 2007, European journal of cancer.

[14]  J. Valcárcel,et al.  Fas-activated Serine/Threonine Kinase (FAST K) Synergizes with TIA-1/TIAR Proteins to Regulate Fas Alternative Splicing* , 2007, Journal of Biological Chemistry.

[15]  Marylène Lejeune,et al.  Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[17]  D. Borghys,et al.  A new approach to the validation of tissue microarrays , 2006, The Journal of pathology.

[18]  Douglas G Altman,et al.  Dichotomizing continuous predictors in multiple regression: a bad idea , 2006, Statistics in medicine.

[19]  Z. Trajanoski,et al.  Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.

[20]  R. Houlston,et al.  Systematic review of microsatellite instability and colorectal cancer prognosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Tollenaar,et al.  Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells , 2004, Cancer Immunology, Immunotherapy.

[22]  S. Mocellin,et al.  Increased TIA‐1 gene expression in the tumor microenvironment after locoregional administration of tumor necrosis factor‐α to patients with soft tissue limb sarcoma , 2003, International journal of cancer.

[23]  D. Mark,et al.  Clinical prediction models: are we building better mousetraps? , 2003, Journal of the American College of Cardiology.

[24]  H. Müller-Hermelink,et al.  Cytotoxic/natural killer cell cutaneous lymphomas , 2003, Cancer.

[25]  J. Valcárcel,et al.  Molecular mechanisms of gene expression regulation by the apoptosis-promoting protein TIA-1 , 2001, Apoptosis.

[26]  J. Fagerberg,et al.  Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma , 1999, Cancer Immunology, Immunotherapy.

[27]  C. Rubio,et al.  Cytotoxic intraepithelial lymphocytes in colorectal polyps and carcinomas. , 1999, Anticancer research.

[28]  A. Viel,et al.  High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. , 1999, The American journal of pathology.

[29]  J. Shetye,et al.  Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  K. Do,et al.  Morphology of sporadic colorectal cancer with DNA replication errors , 1998, Gut.

[31]  C. Melief,et al.  Cancer immunology. , 2011, Current opinion in immunology.

[32]  W. Foulkes,et al.  MSI-H colorectal cancers preferentially retain and expand intraepithelial lymphocytes rather than peripherally derived CD8+ T cells , 2008, Cancer Immunology, Immunotherapy.

[33]  B. O'Sullivan,et al.  Prognostic Factors in Cancer , 1995, UICC International Union Against Cancer / Union Internationale Contre le Cancer.